These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20501655)

  • 1. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
    Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
    J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
    Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
    J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
    Pliyev BK; Antonova OA; Menshikov M
    Mol Immunol; 2011 May; 48(9-10):1168-77. PubMed ID: 21470685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
    Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
    Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
    Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
    J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
    Czekay RP; Loskutoff DJ
    J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts.
    Grove LM; Southern BD; Jin TH; White KE; Paruchuri S; Harel E; Wei Y; Rahaman SO; Gladson CL; Ding Q; Craik CS; Chapman HA; Olman MA
    J Biol Chem; 2014 May; 289(18):12791-804. PubMed ID: 24644284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
    Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
    Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.
    Wei Y; Eble JA; Wang Z; Kreidberg JA; Chapman HA
    Mol Biol Cell; 2001 Oct; 12(10):2975-86. PubMed ID: 11598185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway.
    Cheng X; Shen Z; Yin L; Lu SH; Cui Y
    J Biol Chem; 2009 Nov; 284(45):30897-906. PubMed ID: 19717562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
    Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
    BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.
    Lin CH; Lin HH; Kuo CY; Kao SH
    Oncotarget; 2017 Feb; 8(7):11316-11328. PubMed ID: 28076322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
    Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
    Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.